Soluble ST2 in Patients with Nonvalvular Atrial Fibrillation and Prediction of Heart Failure

Abstract

SummaryAtrial fibrillation (AF) is the most common clinically relevant arrhythmia. AF is a strong independent risk factor for the subsequent development of heart failure (HF). HF and AF can interact to perpetuate and exacerbate each other. Soluble ST2 (sST2) is a biomarker of cardiomyocyte stretch that is useful in the diagnosis and prognosis of HF. Its role in the field of AF has not yet been well investigated. We studied the concentration of sST2 in a cohort of 174 subjects (62.1% men; mean age, 65.6 ± 10.3 years [± standard deviation (SD)]) with nonvalvular AF and 116 age-matched patients with sinus rhythm (SR). Subjects were subdivided into 3 groups: paroxysmal AF, persistent AF, and SR. Plasma sST2 concentrations were measured using an electrochemiluminescence-based immunoassay. The sST2 level was higher in persistent AF patients (P < 0.05) and paroxysmal AF patients (P < 0.05) than in SR patients. No significant difference was found between persistent AF and paroxysmal AF. sST2 was correlated with left atrial diameter (LAD) (r = 0.21; P < 0.01). During a median follow-up time of 6 months, 43 subjects with non-valvular AF in the study had HF. Cox proportional hazard analysis revealed both sST2 and LAD were independent predictors of HF. sST2 concentrations are higher in AF than SR. Plasma sST2 may be a useful biomarker in predicting HF in patients with AF.(Int Heart J 2018; 59: 58-63)

Role of sST2 in predicting recurrence of atrial fibrillation after radiofrequency catheter ablation

“…35 sST2 might be associated with risk of AF emergence and progression. 36 Our study suggested sST2 level between patients with and without abnormalities during endocardial mapping in the first procedure did not reach a significantly difference.…”

Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone

“…sST2 is involved in pathophysiology of cardiac fibrosis and inflammation and is a powerful predictor of adverse outcomes [48]. This concept is true in type 2 AMI too, where its levels seem to be associated with future myocardial remodeling and worse outcome [57]. It is well-known that fibrotic and remodeling processes of the atria promote the maintenance and occurrence of AF [58].…”

Nowe markery biologiczne w kardiologii — czy to właściwy trop?

“…Chen i wsp. [33] badali stężenia sST-2 u pacjentów z AF niezwiązanym ze stenozą mitralną lub protezą zastawkową oraz u pacjentów z rytmem zatokowym. Zaobserwowali wyższe stężenia sST-2 u pacjentów z AF oraz dodatnią korelację z wymiarem lewego przedsionka.…”

“…Nie stwierdzono różnic między pacjentami z napadowym i przetrwałym AF. Podczas 6-miesięcznej obserwacji badacze wykazali, że sST-2 oraz wymiar lewego przedsionka są niezależnymi czynnikami rozwoju niewydolności serca u pacjentów z tak zwanym niezastawkowym AF [33].…”